InvestSMART

Paradigm Biopharmaceuticals Limited (ASX:PAR)

ALERT: Price-sensitive ASX Announcement for PAR
Current share price for PAR : $0.175 -0.225 (-56.25%)+
Announcement
Release
29 Jul 2025 9:26AM
Price at Release
$0.400
Full Release
download
Summary
The June 2025 Quarterly Activities Report & Appendix 4C for Paradigm Biopharmaceuticals Limited details the company’s progress in clinical development, commercial preparation, and financial position. The report highlights continued advancement of Paradigm’s lead program, injectable pentosan polysulfate sodium (iPPS or Zilosul®), for osteoarthritis knee pain. Paradigm discusses completion of patient recruitment in its pivotal Phase 3 clinical trial, regulatory engagement with the FDA and EMA, and ongoing commercial readiness activities. The report also outlines progress in other pipeline indications, ongoing scientific collaborations, and key operational and financial metrics, including cash balance and R&D expenditures. The Appendix 4C provides a summary of the company’s cash flows for the quarter.
Key Points
  • Paradigm completed enrolment of patients in its pivotal Phase 3 clinical trial for iPPS (Zilosul®) in osteoarthritis knee pain.
  • The company engaged with global regulatory agencies, including pre-New Drug Application (pre-NDA) interactions with the FDA and EMA.
  • Preparations for commercialisation of Zilosul® are progressing, including engagement with payers, healthcare professionals, and patient advocacy groups.
  • Paradigm’s pipeline includes ongoing studies in other indications for iPPS, as well as preclinical collaborations.
  • The company’s quarterly report includes financial updates, with a stated cash position and breakdown of R&D and operating expenditures.
  • No significant changes in board or management were reported in the quarter.
  • The Appendix 4C provides a summary of cash flows, with detail on receipts, payments, and net cash used in operating activities.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.